Who are Dupilumab (SAR231893/REGN668)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dupilumab Prefilled Syringe, Dupilumab step-down, Dupilumab (SAR231893), Dupilumab Injectable Product, Dupilumab - Dose Reduction, Dupilumab/Dupixent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dupilumab-sar231893-regn668.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dupilumab (SAR231893/REGN668) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dupilumab (SAR231893/REGN668) (Dupilumab (SAR231893/REGN668)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; IL-4 receptor antagonist. Area: Immunology; Dermatology; Respiratory.

phase 3 Monoclonal antibody; IL-4 receptor antagonist IL-4 receptor alpha (IL-4Rα) Immunology; Dermatology; Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Dupilumab (SAR231893/REGN668) (Dupilumab (SAR231893/REGN668)) — Sanofi. Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dupilumab (SAR231893/REGN668) TARGET	Dupilumab (SAR231893/REGN668)	Sanofi	phase 3	Monoclonal antibody; IL-4 receptor antagonist	IL-4 receptor alpha (IL-4Rα)
Dupilumab Prefilled Syringe	Dupilumab Prefilled Syringe	Jonathan A. Bernstein, MD	marketed	Monoclonal antibody; IL-4 receptor antagonist	IL-4 receptor alpha (IL-4Rα)
Dupilumab step-down	Dupilumab step-down	Nantes University Hospital	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab (SAR231893)	Dupilumab (SAR231893)	Sanofi	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab Injectable Product	Dupilumab Injectable Product	University of Virginia	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab - Dose Reduction	Dupilumab - Dose Reduction	Johns Hopkins University	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab/Dupixent	Dupilumab/Dupixent	McMaster University	phase 3	Monoclonal antibody; IL-4 receptor antagonist	IL-4 receptor alpha (IL-4Rα)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody; IL-4 receptor antagonist class)

Jonathan A. Bernstein, MD · 1 drug in this class
McMaster University · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dupilumab (SAR231893/REGN668) — Competitive Intelligence Brief. https://druglandscape.com/ci/dupilumab-sar231893-regn668. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab